Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASKG 712

Drug Profile

ASKG 712

Alternative Names: AM-712; ASKG-712

Latest Information Update: 14 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AskGene Pharma
  • Class Bispecific antibodies; Drug conjugates; Eye disorder therapies; Monoclonal antibodies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Wet age-related macular degeneration
  • Preclinical Diabetic macular oedema

Most Recent Events

  • 11 Jul 2023 AskGene Pharma and Suzhou Aosaikang Biopharmaceutical plans a phase I trial for Diabetic macular oedema (In adults, In the elderly) in China (Intravitreal) in July 2023 (NCT05940428)
  • 20 Feb 2023 Phase-I clinical trials in Wet age-related macular degeneration in China (Intravitreous) (NCT05456828)
  • 13 Jul 2022 AskGene Pharma plans a phase I trial for Wet age-related macular degeneration (In adults, In elderly) (Intravitreal) in July 2022 (NCT05456828), (ASKG712-CT-I-1)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top